Revolutionizing Biology: Simon Kohl’s Groundbreaking Work in AI-Driven Drug Design
Simon Kohl, the founder and CEO of Latent Labs, has been at the forefront of the transformation of biology through artificial intelligence (AI). With his extensive experience in protein prediction and design, Kohl has made significant contributions to the field, including co-leading Google DeepMind’s protein design team and working on the AlphaFold2 project, which earned Demis Hassabis and John Jumper the 2024 Nobel Prize in Chemistry. According to Kohl, “Having co-developed AlphaFold2, I’ve seen firsthand how A.I. can solve incredibly complex problems.”
Kohl’s work on AlphaFold2’s uncertainty prediction system “pLDDT” and setting up DeepMind’s wet lab at London’s Francis Crick Institute has been instrumental in advancing the field of biology. However, it was the realization that AI could be used to design biological structures from scratch that led Kohl to found Latent Labs. As he notes, “We were at an inflection point where generative A.I. could make biology programmable.” This vision has been supported by Amazon Web Services (AWS) through its Generative A.I. Accelerator, which provided early-stage funding to Latent Labs in 2024.
Latent Labs’ Breakthroughs in Drug Design
In February, Latent Labs raised $50 million in venture capital funding, with angel investors including Google Chief Scientist Jeff Dean, Cohere founder Aidan Gomez, and ElevenLabs founder Mati Staniszewski. The company has made significant strides in drug design, particularly with the launch of LatentX, which has achieved impressive hit rates of 91 percent to 100 percent for macrocycles and 10 percent to 64 percent for mini-binders across seven therapeutic targets in wet lab experiments. Unlike traditional methods, LatentX simultaneously designs the molecular sequence and 3D structure of proteins in real-time, following atomic-level physical rules to create entirely novel molecules. As Kohl explains, “We’re not just understanding nature anymore, we’re becoming capable of authoring it with precision.”
Latent Labs is prioritizing oncology, autoimmune diseases, and rare genetic disorders, areas where conventional drug discovery faces significant challenges. The company is particularly focused on macrocycles, which combine the precision of biologics with the oral deliverability of small molecules. In direct laboratory comparisons, Latent Labs has outperformed results from major technology companies and leading academic institutions, leveraging their team’s AlphaFold experience combined with enterprise-grade platform engineering. According to a study published in the journal Nature, traditional drug discovery hit rates are typically below 1 percent, highlighting the significance of Latent Labs’ achievements.
Democratizing Access to AI-Driven Drug Design
Rather than developing proprietary medicines, Latent Labs licenses its technology through a web-based platform, making advanced AI accessible to academic institutions, biotech startups, and pharmaceutical companies. While making the technology broadly accessible, Latent Labs maintains strict biosafety protocols, actively engages with regulators on dual-use concerns, and validates all computational designs in its physical laboratory to ensure real-world safety. As Kohl notes, “We envision a future where effective therapeutics can be designed entirely in a computer, much like how space missions or semiconductors are designed today.”
Kohl acknowledges the growing complexity of biological systems and the need for equally sophisticated safety frameworks as these powerful generative tools become more widespread. “Biology remains fundamentally messy,” he says. “A.I. currently amplifies our capabilities, but it still requires deep scientific intuition to ask the right questions and interpret what the models tell us.” With Latent Labs at the forefront of this revolution, the future of biology and drug design looks promising, and Kohl’s work is sure to have a lasting impact on the field.
Image Source: observer.com
